tsRNA signatures in cancer

Significance We found that tRNA-derived small RNAs (tsRNAs) are dysregulated in many cancers and that their expression is modulated during cancer development and staging. Indeed, activation of oncogenes and inactivation of tumor suppressors lead to a dysregulation of specific tsRNAs, and tsRNA-KO cells display a specific change in gene-expression profile. Thus tsRNAs could be key effectors in cancer-related pathways. These results indicate active crosstalk between tsRNAs and oncogenes and suggest that tsRNAs could be useful markers for diagnosis or targets for therapy. Additionally, ts-46 and ts-47 affect cell growth in lung cancer cell lines, further confirming the involvement of tsRNAs in cancer pathogenesis. Small, noncoding RNAs are short untranslated RNA molecules, some of which have been associated with cancer development. Recently we showed that a class of small RNAs generated during the maturation process of tRNAs (tRNA-derived small RNAs, hereafter “tsRNAs”) is dysregulated in cancer. Specifically, we uncovered tsRNA signatures in chronic lymphocytic leukemia and lung cancer and demonstrated that the ts-4521/3676 cluster (now called “ts-101” and “ts-53,” respectively), ts-46, and ts-47 are down-regulated in these malignancies. Furthermore, we showed that tsRNAs are similar to Piwi-interacting RNAs (piRNAs) and demonstrated that ts-101 and ts-53 can associate with PiwiL2, a protein involved in the silencing of transposons. In this study, we extended our investigation on tsRNA signatures to samples collected from patients with colon, breast, or ovarian cancer and cell lines harboring specific oncogenic mutations and representing different stages of cancer progression. We detected tsRNA signatures in all patient samples and determined that tsRNA expression is altered upon oncogene activation and during cancer staging. In addition, we generated a knocked-out cell model for ts-101 and ts-46 in HEK-293 cells and found significant differences in gene-expression patterns, with activation of genes involved in cell survival and down-regulation of genes involved in apoptosis and chromatin structure. Finally, we overexpressed ts-46 and ts-47 in two lung cancer cell lines and performed a clonogenic assay to examine their role in cell proliferation. We observed a strong inhibition of colony formation in cells overexpressing these tsRNAs compared with untreated cells, confirming that tsRNAs affect cell growth and survival.

[1]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[2]  P. Dent,et al.  Coordinate regulation of stress- and mitogen-activated protein kinases in the apoptotic actions of ceramide and sphingosine. , 1997, Molecular pharmacology.

[3]  U. Weidle,et al.  Control of cell growth by c-Myc in the absence of cell division , 1999, Current Biology.

[4]  B. Kempkes,et al.  Cell cycle activation by c‐myc in a Burkitt lymphoma model cell line , 2000, International journal of cancer.

[5]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[6]  B. Stoica,et al.  Ceramide-induced neuronal apoptosis is associated with dephosphorylation of Akt, BAD, FKHR, GSK-3β, and induction of the mitochondrial-dependent intrinsic caspase pathway , 2003, Molecular and Cellular Neuroscience.

[7]  Michael D Schaller,et al.  The interplay between Src and integrins in normal and tumor biology , 2004, Oncogene.

[8]  R. Juliano,et al.  Integrin Signaling , 2005, Cancer and Metastasis Reviews.

[9]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[10]  H. Sawai,et al.  Integrin-linked kinase activity is associated with interleukin-1α-induced progressive behavior of pancreatic cancer and poor patient survival , 2006, Oncogene.

[11]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[12]  M. Kester,et al.  Ceramide recruits and activates protein kinase C zeta (PKC zeta) within structured membrane microdomains. , 2007, The Journal of biological chemistry.

[13]  T. Fox,et al.  Ceramide Recruits and Activates Protein Kinase C ζ (PKCζ) within Structured Membrane Microdomains* , 2007, Journal of Biological Chemistry.

[14]  E. Bieberich Ceramide signaling in cancer and stem cells. , 2008, Future lipidology.

[15]  S. Baker,et al.  PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.

[16]  G. Barton,et al.  Filtering of deep sequencing data reveals the existence of abundant Dicer-dependent small RNAs derived from tRNAs. , 2009, RNA.

[17]  A. Malhotra,et al.  A novel class of small RNAs: tRNA-derived RNA fragments (tRFs). , 2009, Genes & development.

[18]  Pavel Ivanov,et al.  Angiogenin-induced tRNA-derived Stress-induced RNAs Promote Stress-induced Stress Granule Assembly* , 2010, The Journal of Biological Chemistry.

[19]  D. Haussecker,et al.  Human tRNA-derived small RNAs in the global regulation of RNA silencing. , 2010, RNA.

[20]  Hui Zhou,et al.  Deep Sequencing of Human Nuclear and Cytoplasmic Small RNAs Reveals an Unexpectedly Complex Subcellular Distribution of miRNAs and tRNA 3′ Trailers , 2010, PloS one.

[21]  Steven P Gygi,et al.  Angiogenin-induced tRNA fragments inhibit translation initiation. , 2011, Molecular cell.

[22]  R. Maraia,et al.  3′ processing of eukaryotic precursor tRNAs , 2011, Wiley interdisciplinary reviews. RNA.

[23]  George A Calin,et al.  Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. , 2011, JAMA.

[24]  P. Soares,et al.  The mTOR Signalling Pathway in Human Cancer , 2012, International journal of molecular sciences.

[25]  Richard J Maraia,et al.  Transcription termination by the eukaryotic RNA polymerase III. , 2013, Biochimica et biophysica acta.

[26]  S. Willard,et al.  Glutamate Signaling in Benign and Malignant Disorders: Current Status, Future Perspectives, and Therapeutic Implications , 2013, International journal of biological sciences.

[27]  Andrea Califano,et al.  tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[28]  C. Heldin,et al.  Targeting the PDGF signaling pathway in tumor treatment , 2013, Cell Communication and Signaling.

[29]  Pavel Ivanov,et al.  tRNA fragments in human health and disease , 2014, FEBS letters.

[30]  Praveen Sethupathy,et al.  tDRmapper: challenges and solutions to mapping, naming, and quantifying tRNA-derived RNAs from human small RNA-sequencing data , 2015, BMC Bioinformatics.

[31]  F. Pan,et al.  Fractionated Ionizing Radiation Promotes Epithelial-Mesenchymal Transition in Human Esophageal Cancer Cells through PTEN Deficiency-Mediated Akt Activation , 2015, PloS one.

[32]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[33]  Chen Huang,et al.  FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF/AKT signaling pathway , 2015, Oncotarget.

[34]  J. Byrd,et al.  TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia , 2015, Proceedings of the National Academy of Sciences.

[35]  Phillipe Loher,et al.  Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers , 2015, Proceedings of the National Academy of Sciences.

[36]  Fabian J Theis,et al.  Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer , 2015, Molecular Cancer.

[37]  Yuan Yuan,et al.  Genetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysis , 2016, Oncotarget.

[38]  A. Guerrero-Zotano,et al.  PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment , 2016, Cancer and Metastasis Reviews.

[39]  Weiguo Qing,et al.  Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation , 2016, Oncotarget.

[40]  Tsutomu Suzuki,et al.  Precursors of tRNAs are stabilized by methylguanosine cap structures. , 2016, Nature chemical biology.

[41]  SHOT-RNAs: A novel class of tRNA-derived functional RNAs expressed in hormone-dependent cancers , 2016, Molecular & cellular oncology.

[42]  Xin He,et al.  IL-4 Inhibits the Biogenesis of an Epigenetically Suppressive PIWI-Interacting RNA To Upregulate CD1a Molecules on Monocytes/Dendritic Cells , 2016, The Journal of Immunology.

[43]  Giovanni Nigita,et al.  Dysregulation of a family of short noncoding RNAs, tsRNAs, in human cancer , 2016, Proceedings of the National Academy of Sciences.

[44]  R. DePinho,et al.  Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer , 2017, Nature.

[45]  S. Pyne,et al.  Sphingosine 1-phosphate and cancer. , 2017, Advances in biological regulation.